These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38071859)

  • 21. Comparative Analysis of the Wako β-Glucan Test and the Fungitell Assay for Diagnosis of Candidemia and Pneumocystis jirovecii Pneumonia.
    Friedrich R; Rappold E; Bogdan C; Held J
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29899003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study.
    Giannella M; Paolucci M; Roncarati G; Vandi G; Pascale R; Trapani F; Bartoletti M; Tedeschi S; Ambretti S; Lewis R; Re MC; Viale P
    J Antimicrob Chemother; 2018 Oct; 73(10):2856-2859. PubMed ID: 29939275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of (1, 3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia.
    Alam FF; Mustafa AS; Khan ZU
    BMC Infect Dis; 2007 Sep; 7():103. PubMed ID: 17784947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative sensitivity of 1,3 beta-D-glucan for common causes of candidaemia in South Africa.
    Chibabhai V; Fadana V; Bosman N; Nana T
    Mycoses; 2019 Nov; 62(11):1023-1028. PubMed ID: 31393662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study.
    Erb T; Mihai S; Strauß R; Herbst L; Castellanos I; Diesch K; Cipa F; Bihlmaier K; Lang A-K; Ganslmayer M; Willam C; Bremer F; Fürst J; Beyer C; Bogdan C; Rath A; Held J
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0072523. PubMed ID: 37823695
    [No Abstract]   [Full Text] [Related]  

  • 26. Epidemiology of bloodstream Candida species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA®) for rapid diagnosis of candidemia.
    Falces-Romero I; Romero-Gómez MP; Moreno-Ramos F; Mingorance J; García-Rodríguez J; Cendejas-Bueno E
    Med Mycol; 2021 Apr; 59(4):350-354. PubMed ID: 32634233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic value of (1,3)-β-D-glucan alone or combined with traditional inflammatory markers in neonatal invasive candidiasis.
    Guo J; Wu Y; Lai W; Lu W; Mu X
    BMC Infect Dis; 2019 Aug; 19(1):716. PubMed ID: 31412796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of β-D-Glucan levels between Candida auris and other Candida species at the time of candidaemia: a retrospective study.
    Farooqi J; Niamatullah H; Irfan S; Zafar A; Malik F; Jabeen K
    Clin Microbiol Infect; 2021 Oct; 27(10):1519.e1-1519.e5. PubMed ID: 34111581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward.
    Clancy CJ; Nguyen MH
    J Antimicrob Chemother; 2018 Mar; 73(suppl_4):iv2-iv5. PubMed ID: 29608754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Methods for Detection of Blood-Borne Candidiasis.
    Clancy CJ; Nguyen MH
    Methods Mol Biol; 2016; 1356():215-38. PubMed ID: 26519076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.
    Bloos F; Held J; Kluge S; Simon P; Kogelmann K; de Heer G; Kuhn SO; Jarczak D; Motsch J; Hempel G; Weiler N; Weyland A; Drüner M; Gründling M; Meybohm P; Richter D; Jaschinski U; Moerer O; Günther U; Schädler D; Weiss R; Putensen C; Castellanos I; Kurzai O; Schlattmann P; Cornely OA; Bauer M; Thomas-Rüddel D;
    Intensive Care Med; 2022 Jul; 48(7):865-875. PubMed ID: 35708758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis.
    Nguyen MH; Wissel MC; Shields RK; Salomoni MA; Hao B; Press EG; Shields RM; Cheng S; Mitsani D; Vadnerkar A; Silveira FP; Kleiboeker SB; Clancy CJ
    Clin Infect Dis; 2012 May; 54(9):1240-8. PubMed ID: 22431804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study.
    Muñoz P; Vena A; Machado M; Gioia F; Martínez-Jiménez MC; Gómez E; Origüen J; Orellana MÁ; López-Medrano F; Fernández-Ruiz M; Merino P; González-Romo F; Frías I; Pérez-Granda MJ; Aguado JM; Fortún J; Bouza E;
    J Antimicrob Chemother; 2018 Mar; 73(suppl_4):iv6-iv12. PubMed ID: 29608751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Performance of the Dynamiker Fungus (1-3)-β-D-Glucan and Fungitell Assay for Diagnosis of Candidemia: Need for New Cut-off Development and Test Validation.
    Yazdanpanah S; Rahbarmah M; Motamedi M; Khodadadi H
    Diagn Microbiol Infect Dis; 2024 Feb; 108(2):116118. PubMed ID: 37992564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early treatment of candidemia in adults: a review.
    Ostrosky-Zeichner L; Kullberg BJ; Bow EJ; Hadley S; León C; Nucci M; Patterson TF; Perfect JR
    Med Mycol; 2011 Feb; 49(2):113-20. PubMed ID: 20818922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections.
    Del Bono V; Delfino E; Furfaro E; Mikulska M; Nicco E; Bruzzi P; Mularoni A; Bassetti M; Viscoli C
    Clin Vaccine Immunol; 2011 Dec; 18(12):2113-7. PubMed ID: 21994353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial.
    Bloos F; Held J; Schlattmann P; Brillinger N; Kurzai O; Cornely OA; Thomas-Rüddel D
    Trials; 2018 Sep; 19(1):472. PubMed ID: 30180873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serological biomarkers of candidemia: a retrospective evaluation of three assays.
    Dichtl K; Seybold U; Wagener J
    Infection; 2019 Apr; 47(2):217-224. PubMed ID: 30264200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization and impact of a rapid Candida panel on antifungal stewardship program within a large community hospital.
    Steuber TD; Tucker-Heard G; Edwards J; Sawyer A; Thottacherry E; Hassoun A
    Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115086. PubMed ID: 32535413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (1,3)-β-D-glucan is able to predict therapeutic failure of patients with candidemia and not only mortality.
    Esteves P; Lopes Lima S; Salles de Azevedo Melo A; Maria Beirão E; Nucci M; Colombo AL
    Mycoses; 2021 Mar; 64(3):264-271. PubMed ID: 33274533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.